Receptor tyrosine kinases in osteosarcoma and Ewing sarcoma

Abstract

Abstract:Osteosarcoma and ewing sarcoma are the two most common types of primary malignant bone tumors. Receptor tyrosine kinases (RTKs), including varieties of cell growth factors and protooncogene products, are the highaffinity cell surface receptors which play an important role in the normal physiological function of cells. A large number of studies have demonstrated that the abnormal RTKs signaling pathways may promote the tumorigenesis and development of osteosarcoma and ewing sarcoma by affecting tumor cell survival, proliferation, invasion and metastasis. Targeting treatment of RTKs is a promising therapeutic approach for osteosarcoma and ewing sarcoma.

Key words:Receptor proteintyrosine kinases,Osteosarcoma,Sarcoma, Ewing′s,Drug therapy

Shen Guoqi, Zhang Chunlin. Receptor tyrosine kinases in osteosarcoma and Ewing sarcoma[J]. Journal of International Oncology, 2015, 42(7): 551-553.

References

［1］ Grohar PJ, Helman LJ. Prospects and challenges for the development of new therapies for Ewing sarcoma［J］. Pharmacol Ther, 2013, (2): 216-224. ［2］ Maniscalco L, Iussich S, Morello E, et al. Increased expression of insulinlike growth factor1 receptor is correlated with worse survival in canine appendicular osteosarcoma［J］. Vet J, 2014, In press. ［3］ Wang YH, Han XD, Qiu Y, et al. Increased expression of insulinlike growth factor1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma［J］. J Surg Oncol, 2012, 105(3): 235-243. ［4］ Scotlandi K, Manara MC, Serra M, et al. Expression of insulinlike growth factor system components in Ewing′s sarcoma and their association with survival［J］. Eur J Cancer, 2011, 47(8): 1258-1266. ［5］ Zhong H, Fazenbaker C, Breen S, et al. Medi573 alone or in combination with mammalian target of rapamycin inhibitors, targets the insulinlike growth factor pathway in sarcomas［J］. Mol Cancer Ther, 2014, 13(11): 2662-2273. ［6］ Bagatell R, Herzog CE, Trippett TM, et al. Pharmacokinetically guided phase 1 trial of the IGF1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors［J］.Clin Cancer Res, 2011, 17(3): 611-619. ［7］ Basu B, Olmos D, de Bono JS. Targeting IGF1R: throwing out the baby with the bathwater?［J］. Br J Cancer, 2011, 104(1): 1-3. ［8］ Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulinlike growth factor Ⅱ as additional treatment targets in human osteosarcoma［J］. Cancer Res, 2009, 69(6): 2443-2452. ［9］ Kuijjer ML, Peterse EF, van den Akker BE, et al. IR/IGF1R signaling as potential target for treatment of highgrade osteosarcoma［J］. BMC Cancer, 2013, 13: 245. ［10］ Puzanov I, Lindsay CR, Goff LW, et al. A phase Ⅰ study of continuous oral dosing of OSI906, a dual inhibitor of insulinlike growth factor1 and insulin receptors in patients with advanced solid tumors［J］.Clin Cancer Res, 2014, In press. ［11］ Fleuren ED, Roeffen MH, Leenders WP, et al. Expression and clinical relevance of MET and ALK in Ewing sarcomas［J］. Int J Cancer, 2013, 133(2): 427-436. ［12］ Lin CH, Guo Y, Ghaffar S, et al. Dkk3, a secreted wnt antagonist, suppresses tumorigenic potential and pulmonary metastasis in osteosarcoma［J］. Sarcoma, 2013, 2013: 147541. ［13］徐秋一, 牟海波, 徐农. 表皮生长因子受体酪氨酸激酶抑制剂的耐药机制及应对策略［J］. 国际肿瘤学杂志, 2012, 39(5): 355-359. ［14］ Chernoguz A, Crawford K, Donovan E, et al. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing′s sarcoma model［J］. J Surg Res, 2012, 173(1): 1-9. ［15］ Wang Q, Cai J, Wang J, et al. MiR143 inhibits EGFRsignalingdependent osteosarcoma invasion［J］. Tumour Biol, 2014, 35(12): 12743-12748. ［16］ Geng YD, Yang L, Zhang C, et al. Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Ⅰ cariside Ⅱ results in reduced cell proliferation of osteosarcoma cells［J］. Food Chem Toxicol, 2014, 73: 7-16. ［17］ Sulzbacher I, Birner P, Dominkus M, et al. Expression of plateletderived growth factoralpha receptor in human osteosarcoma is not a predictor of outcome［J］. Pathology, 2010, 42(7): 664-668. ［18］ Bozzi F, Tamborini E, Negri T, et al. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors［J］. Cancer, 2007, 109(8): 1638-1645. ［19］ Takagi S, Takemoto A, Takami M, et al. Platelets promote osteosarcoma cell growth through activation of the plateletderived growth factor receptorAkt signaling axis［J］. Cancer Sci, 2014, 105(8): 983-988. ［20］ Wang YX, Mandal D, Wang S, et al. Inhibiting plateletderived growth factorbeta reduces Ewing′s sarcoma growth and metastasis in a novel orthotopic human xenograft model［J］. In Vivo, 2009, 23(6): 903-909. ［21］ Yang J, Zhang W. New molecular insights into osteosarcoma targeted therapy［J］. Curr Opin Oncol, 2013, 25(4): 398-406. ［22］ Miiji LN, Petrilli AS, Di Cesare S, et al. Ckit expression in human osteosarcoma and in vitro assays［J］. Int J Clin Exp Pathol, 2011, 4(8): 775-781. ［23］ Zhao H, Li M, Li L, et al. MiR133b is downregulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis［J］. PLoS One, 2013, 8(12): e83571. ［24］ Sampson ER, Martin BA, Morris AE, et al. The orally bioavailable met inhibitor PF2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model［J］. J Bone Miner Res, 2011, 26(6): 12831294. ［25］ Niswander LM, Kim SY. Stratifying osteosarcoma: minimizing and maximizing therapy［J］. Curr Oncol Rep, 2010, 12(4): 266-270.

[1]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[2]	Wang Peixin, Zhao Jun, Xu Shihong, Jiang Zhaoyang, Wang Xiaoqiang, Yang Hongjuan.Progress of ferroptosis-related mechanisms in osteosarcoma[J]. Journal of International Oncology, 2024, 51(5): 308-311.
[3]	Wang Zihao, Wang Yu, Yang Xin, He Yi, Mo Xingkui, Yuan Tao.Research progress on the molecular mechanism and related treatments of ferroptosis in osteosarcoma[J]. Journal of International Oncology, 2024, 51(4): 239-244.
[4]	Yue Hongyun, Zhang Baihong.Differentiation therapies in human cancers[J]. Journal of International Oncology, 2024, 51(2): 109-113.
[5]	Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104.
[6]	Li Chenxi, Zhao Hongwei.Prognosis and influencing factors of platinum sensitive recurrent ovarian cancer treated by secondary cytoreduction surgery in patients with unsatisfactory primary cytoreduction surgery[J]. Journal of International Oncology, 2023, 50(6): 342-347.
[7]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai.Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.
[8]	Ma Xiaoping, Chang Junli, Sun Xingyuan, Yang Yanping.Study progression on mechanism of long non-coding RNAs regulating drug resistance in osteosarcoma[J]. Journal of International Oncology, 2023, 50(1): 51-54.
[9]	Chen Yi, Han Liang, Cai Li.Multivariate analysis of chemotherapy induced oral mucositis in patients with head and neck tumors[J]. Journal of International Oncology, 2022, 49(9): 521-525.
[10]	Chu Xuelei, Mao Yun, Xue Peng, Li Linlu, Chen Meichi, Yuan Chunsheng, Qin Xiaoyan, Zhu Shijie.Effects of chemotherapy dose intensity on short-term efficacy in patients with advanced colon cancer： a study based on real-world data[J]. Journal of International Oncology, 2022, 49(7): 408-415.
[11]	Tang Lin, Xiang Mingyue, Zhang Jianbo, Wang Lili, Gong Heyi, Han Dali.Clinical efficacy and safety of camrelizumab combined with apatinib and chemotherapy as second-line or later therapy in the treatment of HER-2 negative advanced gastric cancer[J]. Journal of International Oncology, 2022, 49(5): 276-281.
[12]	Zhou Renbang, Zhang Zhongchuan, Xu Zhiyuan, Zhu Xunbing.MiR-219a-5p inhibits the proliferation, invasion and migration of osteosarcoma U2OS cells by negatively regulating HMGA2[J]. Journal of International Oncology, 2022, 49(4): 193-198.
[13]	Gao Shile, Lu Donghui, Liu Meiqin, Xu Xingjun, Ma Huan, Zhang Yu.Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer[J]. Journal of International Oncology, 2022, 49(3): 140-145.
[14]	Lao Zheng, Tu Wenyong, Xu Xuanli, Zhang Lin, Shao Ziyang, Shi Huifeng.Nimotuzumab combined with definitive radiotherapy for inoperable locally advanced oral and maxillofacial squamous cell carcinoma[J]. Journal of International Oncology, 2022, 49(11): 665-670.
[15]	Luo Liyun, Lai Canhui, Liang Renpei, Yang Aiwu, Lin Zhimin.Correlation between the expressions of miR-524-5p and SOX9 in advanced gastric cancer and their influences on chemotherapy efficacy and prognosis[J]. Journal of International Oncology, 2022, 49(1): 45-50.